# A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

> **NCT01794507** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 66 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** ABT-199
- **DRUG:** bortezomib
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01794507
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-19
- **Primary completion:** 2019-07-16
- **Final completion:** 2019-07-16
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2021-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01794507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01794507, "A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01794507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*